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Background: Clinical outcomes of new-generation drug-eluting stents (DES), Everolimus-eluting stent (EES) or Resolute
zotarolimus-eluting stent (R-ZES), have been reported. However, angiographic follow-up data of new-generation DES
are limited, especially in Asians. We investigated the angiographic and clinical outcomes of EES and R-ZES in a
real-world setting of Korean patients.
Methods: Angiographic and clinical outcomes of 679 patients (866 lesions) who had been treated with EES or
R-ZES from Jun 2008 to May 2010 were evaluated. The primary analysis was to compare in-segment late loss at
9 months and the secondary analyses were to compare the clinical outcomes.
Results: In-segment late loss at 9-month follow-up angiography was 0.23 ± 0.52 mm for EES and 0.29 ± 0.64 mm
for R-ZES (p = 0.248). In addition, the rate of binary restenosis did not show between-group differences (5.8% vs.
6.8% for EES and R-ZES, respectively, p = 0.716). During a median follow-up of 33 months, there were no significant
differences in Kaplan-Meier estimates of target lesion failure (TLF) (7.5% vs. 7.9% for EES and R-ZES, respectively,
p = 0.578) and patient-oriented composite outcomes (POCO including all-cause death, any myocardial infarction,
and any revascularization, 22.8% vs. 20.1%, p = 0.888). The adjusted hazard ratios for TLF and POCO were 0.875
(95% CI 0.427 - 1.793; p = 0.715) and 1.029 (95% CI 0.642 - 1.650; p = 0.904), respectively, for EES over R-ZES in the
propensity score matched group analysis.
Conclusions: In Korean patients undergoing new-generation DES implantation for coronary artery disease, EES
and R-ZES showed similar angiographic outcomes at 9 months and comparable clinical outcomes during 2.8 years
of median follow-up.
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In the era of drug eluting stents (DES), angiographic and
clinical measures of restenosis have been substantially re-
duced [1-3]. However, long-term clinical outcome analyses
have raised concerns about the serious safety problem of
stent thrombosis [3-5], which has been known to be asso-
ciated with allergic and inflammatory reactions to poly-
mers and incomplete strut endothelialization [6-8]. As a
consequence, DES with a new-generation polymer were
developed, including the Xience V™ everolimus-eluting
stent (EES) (Abbott CardioVascular, CA, USA) and the
Resolute zotarolimus-eluting stent (R-ZES) (Medtronic
CardioVascular, CA, USA). These stents use a cobalt chro-
mium based strut with permanent but biocompatible po-
lymers (poly-vinyl-idene fluoride-co-hexafluoropropylene
[PVDF-HFP] and Biolinx, respectively).[9] Recently, re-
sults of large scale randomized controlled trials (RCTs)
with an ‘all-comers’ design have been reported comparing
the efficacy and safety of EES and R-ZES [10-12]. How-
ever, angiographic outcomes of these two stents have been
limited. In addition, even the RCTs with an ‘all-comers’
design do not include all consecutive patients who are en-
countered in every day clinical practice [13]. Therefore,
the purpose of this study was to evaluate and compare the
angiographic and clinical outcomes of EES and R-ZES in
the unselected Korean patient population.
Methods
Patients population
From June 2008 to May 2010, we prospectively identified
734 patients who were treated by percutaneous coronary
intervention (PCI) with either EES or R-ZES for chronic
stable coronary artery disease or acute coronary syn-
drome, including myocardial infarction (MI) with or
without ST-segment elevation. Patients who were treated
with at least one DES were enrolled in the ‘DES registry
of the Seoul National University Bundang Hospital
(DES-SNUBH)’ at the catheterization laboratory. There
were no restrictions or exclusion criteria for enrollment
regarding the reference vessel diameter, total numbers of
treated lesion or vessels, numbers of stents implanted,
lesion length, referral diagnosis, or comorbidities. Out of
734 patients, 55 patients who were treated with both EES
and R-ZES were excluded from the clinical and angio-
graphic outcomes analyses. Therefore, the main analyzed
cohort was the remaining 679 patients with 866 lesions
(EES 405 patients with 500 lesions; R-ZES 274 patients
with 366 lesions) from the registry. Among the main ana-
lyzed cohort, 138 patients of EES group (34.2%) and 114
patients of R-ZES group (41.6%) were also enrolled to
other Korean multicenter registries (the EXCELLENT and
RESOLUTE-Korea registries) under same inclusion and
no exclusion criteria [14]. All patients provided written in-
formed consent, and the study protocol was approved bythe institutional review board of Seoul National University
Bundang Hospital.
Interventional procedures
Coronary interventions were performed according to
current standard techniques. The choice of the stent,
predilatation, post-stenting adjunctive balloon inflation,
and the use of intravascular ultrasound or glycoprotein
IIb/IIIa inhibitors were all left to the operators’ discretion.
All patients received at least 100 mg of aspirin before the
procedure. A loading dose of 300 to 600 mg of clopidogrel
was administered to all patients who were not on
clopidogrel prior to the procedure. After the procedure, all
patients were given aspirin (at least 100 mg/day) indefin-
itely and clopidogrel (75 mg/day) for at least 1 year after
index procedure. During the procedure, unfractionated
heparin at a dose of 70 to 100U per kilogram of body
weight was administered to achieve and maintain an acti-
vated clotting time of more than 250 seconds.
Clinical and angiographic follow-up and quantitative
coronary angiography
Clinical follow-up after PCI was recommended at 1
month, 6 months, and 1 year and annually thereafter.
Angiographic follow-up was routinely recommended at 9
months, post-PCI or earlier if patients complained of any
ischemic symptoms or if noninvasive evaluation suggested
the presence of ischemia. The follow-up angiography was
performed systematically and in a routine manner, unless
the patient rejected the follow-up procedure or the pa-
tient’s condition was not suitable to undergo coronary
angiography. All patients enrolled in this registry provided
a written informed consent not only for the enrollment
but also for the follow-up angiography. Coronary angiog-
raphy obtained at baseline, immediately postprocedure,
and at follow-up were analyzed quantitatively (by quanti-
tative coronary angiography [QCA]) using the Cardio-
vascular Angiography Analysis System (CAAS) II (Pie
Medical Imaging, Maastricht, Netherlands) by an experi-
enced technician who was not aware of the study purpose.
The minimum lumen diameter (MLD), reference vessel
diameter, percent stenosis, acute gain (defined as the dif-
ference in MLD before and after stent implantation), late
lumen loss (defined as the difference between the
postprocedure and follow-up MLD), and binary restenosis
(defined as stenosis of 50% or more at follow-up angiog-
raphy) were measured [15]. All QCA measurements of the
target lesion were obtained in the in-stent zone, and over
the entire segment including the stent and its 5-mm prox-
imal and distal margins (in-segment zone).
Definitions and outcomes analysis
The stent-related clinical outcome was target lesion fail-
ure (TLF), defined as a composite of cardiac death, MI
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indicated target lesion revascularization by percutaneous
or surgical methods [16]. The patient-related clinical out-
come was patient-oriented composite outcome (POCO)
which included all-cause mortality, any MI (including
nontarget vessel territory), and any revascularization
(including all target and nontarget vessels, regardless of
percutaneous or surgical methods) [16]. Other clinical
outcomes, including MI, stent thrombosis, target lesion
revascularization, and target vessel revascularization
were defined as according to Academic Research Con-
sortium (ARC) definitions [16]. Patients with complex
lesions (considered an off-label indication for use of
both DES) were defined as having at least one of the
following characteristics: serum creatinine concentra-
tion ≥140 umol/L (1.6 mg/dL); left ventricular ejection
fraction (LVEF) < 30%; an acute MI within the previous
72 hours; more than one lesion per vessel; two or more
vessels treated with a stent; a lesion greater than 27 mm;
or a bifurcated lesion, bypass graft, in-stent restenosis, un-
protected left main coronary artery, presence of thrombus,
or total occlusion [11,17].
Statistical analysis
Statistical analyses were performed in three parts. The pri-
mary analysis was to compare the angiographic outcomes
at 9 months and the secondary analyses were to compare
the clinical outcomes. Comparison of angiographic out-
comes between two groups was performed in the crude
population. Clinical outcome analysis was perfomed on 1)
the crude population and 2) the propensity score matched
population. Event rates of clinical outcomes were expressedFigure 1 Flow of participants diagram. Abbreviations: EES, everolimus-elas incidence density (i.e. Kaplan-Meier estimates) and the
log-rank or Breslow test was used to compare between-
group differences. For the subgroup analysis of TLF, Cox
proportional hazard model was used to calculate the haz-
ard ratio of EES compared with R-ZES, and interaction p
values between treatment and each subgroup. Since differ-
ences in baseline characteristics could impact the develop-
ment of clinical outcomes, a 1:1 matched analysis without
replacement was performed using propensity score which
was calculated from the model with 23 covariates
(Additional file 1: Table S1). The log-odds of the probabil-
ity that a patient received an R-ZES were modeled as a
function of the confounders. A caliper width of 0.6 SDs
was used because this value has been shown to eliminate
almost 90% of the bias in the observed confounders [18].
Success of the propensity score matching was assessed by
calculating percentage standardized differences of the base-
line characteristics. A less than 10% difference supports the
assumption of a balance between matched groups [19].
Propensity score adjusted stratified Cox proportional haz-
ard regression model was fitted to compare the clinical
outcomes of the matched EES and R-ZES groups. All prob-
ability values were two-sided and p-values < 0.05 were con-
sidered statistically significant. The statistical package
SPSS, version 18.0 (SPSS Inc., Chicago, IL, USA) and R
programming language, version 2.12.2 (R Foundation for
Statistical Computing) were used for statistical analyses.
Results
Baseline clinical and angiographic characteristics
During the study period, a total of 1,508 patients received
PCI in our institution. One hundred and eighty-oneuting stent; R-ZES, Resolute zotarolimus eluting-stent.
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angioplasty. Of the remaining 1,327 patients who were
treated with DES, 734 patients (55.3%) were treated with
EES or R-ZES. Fifty-five patients were excluded since they
were treated with EES and R-ZES simultaneously. The
flow of participants for the study is presented in Figure 1.
The cohort used for the main analysis consisted of 679 pa-
tients with 866 lesions (EES 500 lesions/405 patients,
R-ZES 366 lesions/274 patients). The baseline clinical
characteristics were similar in both groups, except that the
proportion of patients with multivessel disease was higher
in R-ZES group (Table 1). A total of 501 of 679 (73.8%) pa-
tients were classified as complex, which was distributed
similarly in both group. EES was more frequently im-
planted into the left main coronary lesion and the in-stent
restenosis lesion than R-ZES; however, R-ZES was more
often used for small vessel lesion. As a consequence, the
mean stent diameter was significantly smaller in the R-Table 1 Baseline clinical characteristics of crude population*
EES (N = 405)
Age, years 63.9 ± 11.8
Male 297 (73.3%)
Coexisting condition
Diabetes mellitus 157 (38.8%)
Hypertension 283 (69.9%)
Dyslipidemia 140 (34.6%)
Cerebrovascular disease 35 (8.7%)
Peripheral artery disease 9 (2.2%)
Chronic renal failure 15 (3.7%)
Cardiovascular risk factors
Current smoker 103 (25.4%)
Previous PCI 69 (17.0%)
Previous CABG 5 (1.2%)
Previous MI 33 (8.1%)
Clinical indications
Stable angina 189 (46.7%)
Unstable angina 99 (24.4%)
Acute myocardial infarction 117 (28.9%)
Emergency PCI for acute STEMI 41 (10.1%)
Left ventricular ejection fraction 57.11 ± 10.40
Severe LV dysfunction (LVEF < 30%) 6 (1.5%)
Multivessel disease 275 (67.9%)
Complex patient† 293 (72.3%)
* Data are number (%), unless otherwise indicated. Plus-minus values are means ± S
† Complex patient : Complex patients (= off label use) were defined as having at le
umol/L (1.6 mg/dL) or more; left ventricular ejection fraction < 30%; an acute myoc
two or more vessels treated with a stent; a lesion longer than 27mm; or bifurcated
presence of thrombus, or total occlusion.
Abbreviations: CABG coronary artery bypass graft, EES everolimus-eluting stent, F/U f
ejection fraction, MI myocardial infarction, PCI percutaneous coronary intervention,
ST-segment elevation.ZES group. The mean in-stent and in-segment MLDs after
the procedure were also smaller in R-ZES group than in
EES group, despite the similar acute gains in the two
groups (Table 2).Angiographic outcomes and at 9 months
Angiographic follow-up at 9 months was available in 445
patients with 564 lesions (65.5%) (Figure 1). Baseline clin-
ical and angiographic characteristics of the patient cohort
undergoing QCA analysis at 9 months are listed in
Additional file 1: Table S2 and were similar between groups.
In-segment late loss was 0.23 ± 0.52 mm for EES and
0.29 ± 0.64 mm for R-ZES (p = 0.248). In-stent late loss
showed similar findings (0.24 ± 0.53 mm for EES vs. 0.29 ±
0.58 mm for R-ZES, p = 0.267). In addition, the rate of bin-
ary restenosis (5.8% vs. 6.8%, p = 0.716) did not show
between-group differences, despite significantly smallerR-ZES (N = 274) P value





















ast one of the following characteristics: serum creatinine concentration of 140
ardial infarction within the previous 72 hours; more than one lesion per vessel;
lesion, bypass graft, in-stent restenosis, unprotected left main coronary artery,
ollow-up, IQR interquartile range, LV left ventricle, LVEF left ventricular
R-ZES Resolute zotarolimus eluting-stent, STEMI myocardial infarction with
Table 2 Baseline lesional characteristics and quantitative coronary angiography data of crude population*
EES (N = 500) R-ZES (N = 366) P value
Before index procedure
Target vessel location 0.509
Left main 32 (6.4%) 11 (3.0%)
LAD 252 (50.4%) 168 (45.9%)
LCX 109 (21.8%) 95 (26.0%)
RCA 135 (27.0%) 100 (27.3%)
Type B2 or C lesions† 315 (63.0%) 227 (62.0%) 0.769
In-stent restenosis 39 (7.8%) 15 (4.1%) 0.032
Chronic total occlusion 14 (2.8%) 20 (5.5%) 0.052
Bifurcation‡ 31 (6.2%) 31 (8.5%) 0.201
Small vessel§ 169 (33.8%) 167 (45.6%) 0.001
Long lesion¶ 102 (20.4%) 69 (18.9%) 0.572
Lesion length, mm 20.63 ± 9.89 21.10 ± 10.32 0.530
Reference diameter, mm 2.90 ± 0.59 2.79 ± 0.58 0.012
Minimum lumen diameter, mm 0.75 ± 0.49 0.72 ± 0.51 0.352
Percent stenosis, % 79.60 ± 15.35 78.03 ± 17.05 0.162
After index procedure
Number of stents/lesion 1.23 ± 0.47 1.20 ± 0.43 0.226
Total stent length/lesion, mm 27.83 ± 13.33 28.16 ± 12.55 0.717
Pressure deployment, atm 15.02 ± 5.94 15.12 ± 4.74 0.783
Mean stent diameter/lesion, mm 3.11 ± 0.45 2.91 ± 0.40 < 0.001
Minimum lumen diameter, mm
In-stent 2.61 ± 0.47 2.51 ± 0.43 0.001
In-segment 2.60 ± 0.48 2.49 ± 0.45 0.001
Percent stenosis, %
In-stent 12.85 ± 7.00 11.71 ± 7.11 0.019
In-segment 12.35 ± 7.32 11.38 ± 7.58 0.063
Acute gain, mm
In-stent 1.88 ± 0.61 1.80 ± 0.55 0.094
In-segment 1.86 ± 0.63 1.79 ± 0.57 0.128
* Data are number (%), unless otherwise indicated. Plus-minus values are means ± SD.
† Type B2 or C lesions according to ACC/AHA classification.
‡ Bifurcation means bifurcated lesion that have been treated solely by drug-eluting stents.
§ Small vessel denotes lesion with reference diameter < 2.75 mm.
¶ Long lesion denotes lesion with length ≥ 28 mm.
Abbreviations: EES everolimus-eluting stent, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, R-ZES Resolute
zotarolimus eluting-stent.
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0.60 mm vs. 2.77 ± 0.50 mm, p = 0.038) (Table 3).
Clinical outcomes up to 3 years of follow-up
The median follow-up duration after index procedure was
1014 days (33 months, interquartile range 27.0–38.0
months). There were no significant differences in Kaplan-
Meier estimates of TLF (7.5% in the EES group vs. 7.9% in
the R-ZES group, p = 0.578) or POCO (22.8% vs. 20.1%,
p = 0.888). A total of 9 patients developed ARC-defined
definite or probable stent thrombosis. Kaplan-Meierestimates of definite or probable stent thrombosis were
not significantly different between the groups (1.5% vs.
1.8%; p = 0.741) (Figure 2 and Table 4). Detailed descrip-
tions of the cases are presented in Additional file 1:
Table S3.
Subgroup analysis
Exploratory subgroup analyses regarding TLF were
performed according to the presence of diabetes, acute
myocardial infarction (< 72 hours), multivessel PCI, long
lesion (≥ 28 mm), and small vessel (< 2.75 mm). There
Table 3 Angiographic outcomes with quantitative coronary angiography data at 9 months follow-up*
EES (Lesion n = 324) R-ZES (Lesion n = 240) P value
Number of patients 264 (65.2%) 181 (66.1%) 0.869
Before index procedure
Lesion length, mm 20.33 ± 10.04 20.89 ± 8.89 0.528
Reference diameter, mm 2.88 ± 0.60 2.77 ± 0.50 0.038
Minimum lumen diameter, mm 0.73 ± 0.50 0.71 ± 0.53 0.769
Percent stenosis, % 80.73 ± 14.79 77.64 ± 17.24 0.024
After index procedure
Total stent length, mm 27.03 ± 12.91 28.61 ± 12.88 0.153
Number of stents/lesion 1.20 ± 0.45 1.20 ± 0.43 0.889
Minimum lumen diameter, mm
In-stent 2.60 ± 0.48 2.53 ± 0.43 0.061
In-segment 2.59 ± 0.50 2.50 ± 0.46 0.030
Percent stenosis, %
In-stent 13.03 ± 6.92 11.17 ± 6.26 0.001
In-segment 12.60 ± 7.20 11.27 ± 7.53 0.037
Acute gain, mm
In-stent 1.89 ± 0.64 1.83 ± 0.56 0.284
In-segment 1.87 ± 0.67 1.80 ± 0.60 0.237
Follow-up procedure
Minimum lumen diameter, mm
In-stent 2.37 ± 0.66 2.23 ± 0.64 0.017
In-segment 2.36 ± 0.66 2.20 ± 0.66 0.006
Percent stenosis, %
In-stent 20.65 ± 17.52 20.50 ± 19.23 0.925
In-segment 19.41 ± 17.30 20.68 ± 19.19 0.431
Late lumen loss, mm
In-stent 0.24 ± 0.53 0.29 ± 0.58 0.267
In-segment 0.23 ± 0.52 0.29 ± 0.64 0.248
Loss index
In-stent 0.19 ± 0.78 0.09 ± 0.57 0.129
In-segment 0.15 ± 0.81 0.07 ± 0.99 0.093
Binary restenosis, %
In-stent 18 (5.8%) 15 (6.8%) 0.716
In-segment 17 (5.6%) 15 (6.9%) 0.582
* Among a total of 679 patients, angiographic follow-up was available in 65.5% of patients (445 patients with 561 lesions). Data are number (%), unless otherwise
indicated. Plus-minus values are means ± SD.
Abbreviations: EES everolimus-eluting stent, R-ZES Resolute zotarolimus eluting-stent.
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and the results were consistent across all subgroups,
with no significant interaction p values (Figure 3).
Propensity score matched group analysis
Matching by propensity score with caliper width of 0.6 SDs
yielded 249 EES patients matched to 249 R-ZES patients.
Standardized differences of baseline clinical and angio-
graphic characteristics were less than 10%, and both groupswere more balanced than before matching, with the excep-
tion of bifurcation lesion (percent standardized difference
12.91%, Additional file 1: Table S4). The comparable inci-
dences of clinical outcomes were corroborated in propen-
sity score matched group analysis. The adjusted hazard
ratio for TLF and POCO were 0.875 (95% CI 0.427 - 1.793;
p = 0.715) and 1.029 (95% CI 0.642 - 1.650; p = 0.904), re-
spectively, for EES over R-ZES (Table 5). Among the
propensity-score matched population, 325 patients (65.3%
Figure 2 Survival analysis for target lesion failure and patient-oriented composite outcome up to 3 years of follow-up. A) Target lesion
failure. B) Patient-oriented composite outcome. C) Target vessel myocardial infarction D) Cardiac death E) Target lesion revascularization. Target
lesion failure defined as a composite of cardiac death, myocardial infarction (not clearly attributed to a nontarget vessel), or clinically indicated
target lesion revascularization by percutaneous or surgical methods. Patient-oriented composite outcome included all-cause mortality, any
myocardial infarction (includes nontarget vessel territory), and any revascularization (includes all target and nontarget vessel, regardless of
percutaneous or surgical methods). Log rank p value or Breslow p value were presented. Abbreviations: EES, everolimus-eluting stent; R-ZES,
Resolute zotarolimus eluting-stent.
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raphy. Angiographic outcomes including in-stent and in-
segment late loss, and the rate of binary restenosis were
comparable between the two groups (data not shown).
Discussion
This observational study compared the clinical and angio-
graphic outcomes of two new-generation DES—the
Xience V EES and the Resolute ZES—in an unselected pa-
tient population without exclusion criteria. There was no
significant difference in the primary angiographic out-
come, in-segment late loss at 9 months, between the two
stent groups. The stent- and patient-related clinical out-
comes (TLF and POCO, respectively) were comparable up
to 3 years of follow-up, which were corroborated by the
similar results from the propensity score matched cohort.
In our study, angiographic follow-up data were available
in a relatively larger proportion of patients (445 among679 patients, 65.5%) compared with previous RCT analyz-
ing the angiographic outcomes of EES and R-ZES in all-
comers population (RESOLUTE All Comers trial (272 pa-
tients among 2292 patients, 11.9%) [10]. To the best of
our knowledge, this study includes the largest angio-
graphic cohort for the comparison of EES and R-ZES.
Although there were several significant differences in
baseline clinical and angiographic characteristics between
the two groups, which is an inherent limitation of non-
randomized studies, the angiographic outcomes, not only
the binary restenosis but also the in-stent or in-segment
late loss at 9 months, were comparable. Our angiographic
follow-up data, performed in a relatively large patient
population with complex coronary anatomy, support the
previous result of RESOLUTE ALL Comers trial, which
demonstrated no difference between EES and R-ZES in in-
hibitory effect on neointimal hyperplasia [10]. With regard
to the differences in baseline clinical and angiographic
Table 4 Clinical outcomes in crude population up to 3 years of follow-up (Kaplan-Meier estimates and log-rank
p value)*
EES (N = 405) R-ZES (N = 274) P value
All cause death 4.6% (16) 3.9% (9) 0.753
Cardiac death 1.7% (6) 1.7% (4) 0.962
Any myocardial infarction 2.1% (7) 1.9% (4) 0.858
Target vessel 1.8% (6) 1.4% (3) 0.732
Non Target vessel 0.3% (1) 0.4% (1) 0.760
MI due to ST 1.0% (3) 1.4% (3) 0.564
Target lesion revascularization 5.6% (18) 6.6% (16) 0.333
Target vessel revascularization 7.7% (26) 8.3% (20) 0.539
Any revascularization 19.2% (54) 17.4% (37) 0.603
Target lesion failure† 7.5% (25) 7.9% (19) 0.578
Patient-oriented composite outcome‡ 22.8% (69) 20.1% (44) 0.888
Definite ST 1.3% (4) 0.9% (2) 0.789
Acute (0–1 day) 0.0% 0.0% NA
Subacute (2–30 days) 0.5% (2) 0.0% 0.249
Late (31–360 days) 0.3% (1) 0.0% 0.418
Very late (≥ 361 days) 0.5% (1) 0.9% (2) 0.296
Probable ST 0.3% (1) 0.9% (2) 0.344
Acute (0–1 day) 0.3% (1) 0.0% 0.411
Subacute (2–30 days) 0.0% 0.4% (1) § 0.221
Late (31–360 days) 0.0% 0.0% NA
Very late (≥ 361 days) 0.0% 0.5% (1) 0.215
Definite/Probable ST 1.5% (5) 1.8% (4) 0.741
* Clinical outcomes were presented as cumulative incidence (Kaplan-Meier estimates, %) of primary and secondary clinical outcomes calculated. Numbers of total
events are presented in parentheses. P values are log-rank p value or Breslow p value.
† Target lesion failure defined as a composite of cardiac death, myocardial infarction (not clearly attributed to a nontarget vessel), or clinically indicated target
lesion revascularization by percutaneous or surgical methods at 3 years.
‡ Patient-oriented composite outcomes included all-cause mortality, any myocardial infarction (includes nontarget vessel territory), and any revascularization
(includes all target and nontarget vessel, regardless of percutaneous or surgical methods).
§ Subacute stent thrombosis, presented with sudden cardiac arrest which occurred at 6 days after percutaneous coronary intervention.
Abbreviations: EES everolimus-eluting stent, MI myocardial infarction, R-ZES Resolute zotarolimus eluting-stent, ST stent thrombosis, EES everolimus-eluting stent.
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might stem from the operator’s experiences with the stent
utilized. We postulate that the preference for EES in left
main and restenotic lesions may be explained by longer
experience with EES, which has been introduced earlier
than R-ZES. In contrast, the previous experience with ZES
(Endeavor® Splint) with better deliverability compared to
the first generation DES may have contributed to favoring
R-ZES in small and multivessel disease.
Previously, RESOLUTE All Comers trials reported that
R-ZES and EES showed similar safety and efficacy out-
comes up to 2-year follow-up [10,11]. Although well-
designed RCTs are the gold standard to evaluate safety
and efficacy of therapeutic options, these may not reflect
the actual clinical practice due to highly selective inclusion
criteria. Even RESOLUTE All Comers trial—a RCT with
an ‘all-comers’ design—was not able to enroll allconsecutive patients, but included only 44% of them [13].
While we prepared this report, the result of TWENTE
trial was published, and they also reported the similar clin-
ical outcomes for both stent types at 1 year [11]. Although,
they enrolled more than 80% of all eligible patients and
77% of the enrolled patients were with off-label indication
for DES, they excluded acute ST-segment elevation MI pa-
tients. In this study, we tried to evaluate and reflect rou-
tine ‘real world’ clinical practice as much as possible and
the patients were enrolled at the time of the index pro-
cedure without exclusion criteria. As a result, a variety of
patients with differing clinical and angiographic characteris-
tics, such as acute MI, severe LV dysfunction, left main cor-
onary artery disease, small vessel disease, long lesions, or
in-stent restenosis lesions, were included for this analysis.
Notably, the overall proportion of acute coronary syn-
drome was 53.9% (366/679 patients), those with diabetes
Figure 3 Subgroup analysis. Abbreviations: EES, everolimus-eluting stent; R-ZES, Resolute zotarolimus eluting-stent; HR, hazard ratio;
CI, confidence interval; AMI, acute myocardial infarction; PCI, percutaneous coronary intervention.
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http://www.biomedcentral.com/1471-2261/13/65mellitus was 38.0% (258/679 patients), and the majority of
the population (73.8%) had at least one criterion for com-
plex patients or lesional characteristics. The large propor-
tion of high-risk patients and lesions implies that our
study population well reflects real-world practice in Korea
without any exclusion or restriction.
It is noteworthy that, in a 2-year follow-up of the RESO-
LUTE All Comers trial, Silber et al. reported substantially
higher rates of patient-related outcome than stent-related
outcomes [11]. In agreement with the above study, we alsoTable 5 Clinical outcomes during follow-up period in the pro
EES R-ZES
All cause death 4.9 (11) 3.7 (8)
Cardiac death 2.2 (5) 1.9 (4)
Any myocardial infarction 2.7 (5) 2.0 (4)
Target vessel 2.2 (4) 1.6 (3)
Target lesion revascularization 5.7 (10) 7.2 (16)
Target vessel revascularization 7.4 (14) 9.1 (20)
Any revascularization 22.3 (35) 18.6 (36)
Target lesion failure 8.4 (16) 8.6 (19)
Patient-oriented outcome 26.4 (46) 21.1 (42)
* Hazard ratio was calculated with stratified Cox proportional hazard regression, val
Abbreviations: CI confidence interval, EES everolimus-eluting stent, HR hazard ratio, Rnoticed substantial difference between the rates of patient-
oriented composite outcomes and stent-related outcomes
(TLF). These findings emphasize the importance of sec-
ondary prevention of cardiac risk factors and overall med-
ical management of non-cardiac comorbidities [11].
Limitations
Some limitations of this study should be considered. First,
this study was a non-randomized observational study
using a single center registry data with a relatively smallpensity score matched groups (249 pairs)










ues are hazard ratio of EES compared with R-ZES.
-ZES Resolute zotarolimus-eluting stent.
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http://www.biomedcentral.com/1471-2261/13/65number of patients and was not sufficiently powered to
compare clinical outcomes between two stent groups due
to limited sample size and low event rates. Second, even
though we used propensity score matching and stratified
Cox proportional hazard regression modeling to minimize
the allocation bias and control for potential confounding
variables, the possibilities of uncontrolled and unknown
confounding factors need to be considered. Third, because
data were from observational registries, the clinical events
may not have been captured with scrutiny and patient
follow-up may not have been as tight as would be in RCTs.
Although we analyzed clinical outcomes up to 3 years of
follow-up, a considerable number was lost to follow-up
during the second year of follow-up. This can also be an-
other source of bias and may explain lower TLF rate com-
pared with that of RESOLUTE All Comer study at 2 year.
However, censoring distributions of the two groups for the
clinical outcomes were similar and little influence on the
comparisons of two groups is expected. Fourth, the cri-
teria of complex patients or lesional characteristics could
not include homogeneous patient population. For ex-
ample, a patient with severe renal insufficiency which has
(at the same time) an acute MI due to left main disease is
really different from a patient which receives a stent in an
obtuse marginal artery because of in-stent re-stenosis, but
both patients would be represented as the same complex
group. Fifth, QCA analysis was not performed by an inde-
pendent core laboratory, but rather by a single analyst. Al-
though the analyst was blinded to the allocated stent
group, systematic error cannot be completely excluded. In
addition, there were no available data about intravascular
ultrasound guidance PCI or the use of post-adjunctive bal-
loon which is important for the optimal procedure. At last,
a relatively high number of clinical events occurred
around the ninth month during the follow-up, when the
follow-up angiography was performed. It has been demon-
strated that mandatory angiographic follow-up increases
rates of revascularization [20]. We also speculate that the
so-called ‘oculo-stenotic reflex’ may have contributed to
the revascularization rates in this study. Therefore the
present results cannot be directly extrapolated to routine
clinical practice where mandatory follow-up angiography
is not performed.Conclusion
In Korean patients undergoing new-generation DES im-
plantation for coronary artery disease, EES and R-ZES
showed similar angiographic outcomes at 9 months and
comparable clinical outcomes during 2.8 years of median
follow-up. This study was only powered in comparison
of angiographic outcome, 9-month in-segment late loss.
For the comparison of clinical outcomes, larger study
with adequate patient’s number is warranted.Additional files
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